357 related articles for article (PubMed ID: 31017831)
1. Development of novel vaccines against human cytomegalovirus.
Cui X; Snapper CM
Hum Vaccin Immunother; 2019; 15(11):2673-2683. PubMed ID: 31017831
[TBL] [Abstract][Full Text] [Related]
2. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
3. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
[TBL] [Abstract][Full Text] [Related]
4. Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.
Plachter B
Med Microbiol Immunol; 2016 Dec; 205(6):537-547. PubMed ID: 27519596
[TBL] [Abstract][Full Text] [Related]
5. Dominant Antiviral CD8
Pardieck IN; van Duikeren S; Veerkamp DMB; Brasem DJ; Redeker A; van Bergen J; Han W; Ossendorp F; Zondag G; Arens R
Front Immunol; 2022; 13():680559. PubMed ID: 35154089
[TBL] [Abstract][Full Text] [Related]
6. Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines.
Boppana SB; Britt WJ
Methods Mol Biol; 2021; 2244():403-463. PubMed ID: 33555597
[TBL] [Abstract][Full Text] [Related]
7. Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.
Xia L; Su R; An Z; Fu TM; Luo W
Hum Vaccin Immunother; 2018 Feb; 14(2):292-303. PubMed ID: 29053403
[TBL] [Abstract][Full Text] [Related]
8. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine.
Gerna G; Lilleri D
New Microbiol; 2019 Jan; 42(1):1-20. PubMed ID: 30671581
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
[TBL] [Abstract][Full Text] [Related]
10. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.
John S; Yuzhakov O; Woods A; Deterling J; Hassett K; Shaw CA; Ciaramella G
Vaccine; 2018 Mar; 36(12):1689-1699. PubMed ID: 29456015
[TBL] [Abstract][Full Text] [Related]
11. Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.
Perotti M; Perez L
Viruses; 2019 Dec; 12(1):. PubMed ID: 31905677
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus vaccine development.
Schleiss MR
Curr Top Microbiol Immunol; 2008; 325():361-82. PubMed ID: 18637516
[TBL] [Abstract][Full Text] [Related]
13. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
[TBL] [Abstract][Full Text] [Related]
14. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
[TBL] [Abstract][Full Text] [Related]
15. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus Vaccines: Current Status and Future Prospects.
Anderholm KM; Bierle CJ; Schleiss MR
Drugs; 2016 Nov; 76(17):1625-1645. PubMed ID: 27882457
[TBL] [Abstract][Full Text] [Related]
17. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
18. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
[TBL] [Abstract][Full Text] [Related]
19. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease.
Fu TM; An Z; Wang D
Vaccine; 2014 May; 32(22):2525-33. PubMed ID: 24681264
[TBL] [Abstract][Full Text] [Related]
20. Exploiting viral natural history for vaccine development.
Barry PA
Med Microbiol Immunol; 2015 Jun; 204(3):255-62. PubMed ID: 25794555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
